Comment diagnostiquer une expression anormale de CD274 ?
Des tests immunohistochimiques peuvent être utilisés pour détecter CD274 dans les tissus.
Antigène CD274Immunohistochimie
#2
Quels tests sanguins sont utilisés pour CD274 ?
Des dosages de cytokines et des tests de surface cellulaire peuvent évaluer CD274.
CytokinesTests sanguins
#3
CD274 est-il associé à des biomarqueurs spécifiques ?
Oui, CD274 est souvent associé à des biomarqueurs de cancer comme PD-1.
BiomarqueursCancer
#4
Quels types de cancers montrent une surexpression de CD274 ?
Les cancers du poumon, du sein et de la vessie montrent souvent une surexpression de CD274.
Cancer du poumonCancer du sein
#5
Comment évaluer l'impact de CD274 sur le système immunitaire ?
Des études fonctionnelles sur les lymphocytes T peuvent évaluer l'impact de CD274.
Lymphocytes TSystème immunitaire
Symptômes
5
#1
Quels symptômes sont liés à une surexpression de CD274 ?
Une surexpression de CD274 peut entraîner une immunosuppression et des infections fréquentes.
ImmunosuppressionInfections
#2
CD274 influence-t-il les symptômes des maladies auto-immunes ?
Oui, CD274 peut exacerber les symptômes des maladies auto-immunes en inhibant les cellules T.
Maladies auto-immunesCellules T
#3
Y a-t-il des symptômes spécifiques au cancer liés à CD274 ?
Les symptômes peuvent inclure la fatigue, la perte de poids et des douleurs localisées.
FatigueCancer
#4
Comment CD274 affecte-t-il la réponse aux infections ?
Une expression élevée de CD274 peut réduire l'efficacité de la réponse immunitaire aux infections.
Réponse immunitaireInfections
#5
Les symptômes de CD274 sont-ils visibles cliniquement ?
Non, CD274 n'a pas de symptômes visibles, mais son impact est observé par des tests.
Tests cliniquesSymptômes
Prévention
5
#1
Peut-on prévenir l'expression de CD274 ?
Il n'existe pas de méthode spécifique pour prévenir l'expression de CD274.
PréventionExpression génique
#2
Comment un mode de vie sain influence-t-il CD274 ?
Un mode de vie sain peut renforcer le système immunitaire, potentiellement régulant CD274.
Mode de vie sainSystème immunitaire
#3
Y a-t-il des vaccins ciblant CD274 ?
Actuellement, il n'existe pas de vaccins spécifiquement ciblant CD274.
VaccinsAntigènes
#4
La détection précoce des cancers aide-t-elle à gérer CD274 ?
Oui, la détection précoce peut permettre une intervention rapide sur l'expression de CD274.
Détection précoceGestion du cancer
#5
Les habitudes alimentaires influencent-elles CD274 ?
Certaines études suggèrent que l'alimentation peut moduler l'expression de CD274.
Habitudes alimentairesExpression génique
Traitements
5
#1
Quels traitements ciblent CD274 ?
Les inhibiteurs de PD-1 et PD-L1, comme le pembrolizumab, ciblent CD274.
Inhibiteurs de PD-1Pembrolizumab
#2
Comment les thérapies immunologiques agissent-elles sur CD274 ?
Elles bloquent l'interaction entre CD274 et PD-1, stimulant ainsi la réponse immunitaire.
Thérapies immunologiquesRéponse immunitaire
#3
CD274 peut-il être une cible pour la thérapie génique ?
Des recherches explorent la thérapie génique pour moduler l'expression de CD274.
Thérapie géniqueExpression génique
#4
Quels effets secondaires sont associés aux traitements ciblant CD274 ?
Les effets secondaires peuvent inclure des réactions auto-immunes et des inflammations.
Effets secondairesRéactions auto-immunes
#5
Les traitements de CD274 sont-ils efficaces pour tous les cancers ?
Non, l'efficacité varie selon le type de cancer et le profil immunitaire du patient.
Efficacité des traitementsProfil immunitaire
Complications
5
#1
Quelles complications sont liées à une surexpression de CD274 ?
Les complications incluent une immunosuppression accrue et une progression tumorale.
ImmunosuppressionProgression tumorale
#2
CD274 peut-il aggraver des maladies existantes ?
Oui, CD274 peut aggraver des maladies auto-immunes et des infections chroniques.
Maladies auto-immunesInfections chroniques
#3
Y a-t-il des risques de résistance aux traitements avec CD274 ?
Oui, la surexpression de CD274 peut entraîner une résistance aux thérapies immunologiques.
Résistance aux traitementsThérapies immunologiques
#4
Comment CD274 influence-t-il la survie des patients ?
Une expression élevée de CD274 est souvent associée à un pronostic défavorable dans le cancer.
Survie des patientsPronostic
#5
Les complications de CD274 sont-elles réversibles ?
Certaines complications peuvent être réversibles avec un traitement approprié.
ComplicationsTraitement approprié
Facteurs de risque
5
#1
Quels facteurs augmentent le risque d'expression de CD274 ?
Les facteurs incluent des antécédents de cancer, des infections chroniques et l'âge.
Facteurs de risqueAntécédents de cancer
#2
Le tabagisme influence-t-il CD274 ?
Oui, le tabagisme peut augmenter l'expression de CD274, surtout dans le cancer du poumon.
TabagismeCancer du poumon
#3
Y a-t-il un lien entre l'obésité et CD274 ?
Des études montrent que l'obésité peut être associée à une expression accrue de CD274.
ObésitéExpression génique
#4
Les infections virales affectent-elles CD274 ?
Oui, certaines infections virales peuvent induire l'expression de CD274 dans les cellules immunitaires.
Infections viralesCellules immunitaires
#5
Le stress chronique influence-t-il CD274 ?
Le stress chronique peut moduler l'expression de CD274, affectant la réponse immunitaire.
Stress chroniqueRéponse immunitaire
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigène CD274 : Questions médicales les plus fréquentes",
"headline": "Antigène CD274 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigène CD274 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-16",
"dateModified": "2025-05-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigène CD274"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antigènes B7",
"url": "https://questionsmedicales.fr/mesh/D060887",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes B7",
"code": {
"@type": "MedicalCode",
"code": "D060887",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.168"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigène CD274",
"alternateName": "B7-H1 Antigen",
"code": {
"@type": "MedicalCode",
"code": "D060890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Soldano Ferrone",
"url": "https://questionsmedicales.fr/author/Soldano%20Ferrone",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Haidong Dong",
"url": "https://questionsmedicales.fr/author/Haidong%20Dong",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Mayo Clinic, Rochester, MN, USA."
}
},
{
"@type": "Person",
"name": "Hongwei Du",
"url": "https://questionsmedicales.fr/author/Hongwei%20Du",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA."
}
},
{
"@type": "Person",
"name": "Barbara Savoldo",
"url": "https://questionsmedicales.fr/author/Barbara%20Savoldo",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA."
}
},
{
"@type": "Person",
"name": "Gianpietro Dotti",
"url": "https://questionsmedicales.fr/author/Gianpietro%20Dotti",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA. Electronic address: gdotti@med.unc.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Understanding triage assessment of acuity by emergency nurses at initial adult patient presentation: A qualitative systematic review.",
"datePublished": "2023-09-14",
"url": "https://questionsmedicales.fr/article/37716173",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ienj.2023.101334"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association between initial presenting level of consciousness and patient acuity - A potential application for secondary triage in emergency ambulance calls.",
"datePublished": "2022-12-07",
"url": "https://questionsmedicales.fr/article/36496330",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.auec.2022.11.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "Use of a Large Language Model to Assess Clinical Acuity of Adults in the Emergency Department.",
"datePublished": "2024-05-01",
"url": "https://questionsmedicales.fr/article/38713466",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jamanetworkopen.2024.8895"
}
},
{
"@type": "ScholarlyArticle",
"name": "Redirection of low-acuity emergency department patients to nearby medical clinics using an electronic medical support system: effects on emergency department performance indicators.",
"datePublished": "2024-09-13",
"url": "https://questionsmedicales.fr/article/39272018",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12873-024-01080-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "\"I do not know the advantages of having a general practitioner\" - a qualitative study exploring the views of low-acuity emergency patients without a regular general practitioner toward primary care.",
"datePublished": "2024-05-15",
"url": "https://questionsmedicales.fr/article/38750500",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12913-024-10977-2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Antigènes B7",
"item": "https://questionsmedicales.fr/mesh/D060887"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antigène CD274",
"item": "https://questionsmedicales.fr/mesh/D060890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigène CD274 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigène CD274",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigène CD274",
"description": "Comment diagnostiquer une expression anormale de CD274 ?\nQuels tests sanguins sont utilisés pour CD274 ?\nCD274 est-il associé à des biomarqueurs spécifiques ?\nQuels types de cancers montrent une surexpression de CD274 ?\nComment évaluer l'impact de CD274 sur le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Patient+Acuity#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigène CD274",
"description": "Quels symptômes sont liés à une surexpression de CD274 ?\nCD274 influence-t-il les symptômes des maladies auto-immunes ?\nY a-t-il des symptômes spécifiques au cancer liés à CD274 ?\nComment CD274 affecte-t-il la réponse aux infections ?\nLes symptômes de CD274 sont-ils visibles cliniquement ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Patient+Acuity#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigène CD274",
"description": "Peut-on prévenir l'expression de CD274 ?\nComment un mode de vie sain influence-t-il CD274 ?\nY a-t-il des vaccins ciblant CD274 ?\nLa détection précoce des cancers aide-t-elle à gérer CD274 ?\nLes habitudes alimentaires influencent-elles CD274 ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Patient+Acuity#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigène CD274",
"description": "Quels traitements ciblent CD274 ?\nComment les thérapies immunologiques agissent-elles sur CD274 ?\nCD274 peut-il être une cible pour la thérapie génique ?\nQuels effets secondaires sont associés aux traitements ciblant CD274 ?\nLes traitements de CD274 sont-ils efficaces pour tous les cancers ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Patient+Acuity#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigène CD274",
"description": "Quelles complications sont liées à une surexpression de CD274 ?\nCD274 peut-il aggraver des maladies existantes ?\nY a-t-il des risques de résistance aux traitements avec CD274 ?\nComment CD274 influence-t-il la survie des patients ?\nLes complications de CD274 sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Patient+Acuity#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigène CD274",
"description": "Quels facteurs augmentent le risque d'expression de CD274 ?\nLe tabagisme influence-t-il CD274 ?\nY a-t-il un lien entre l'obésité et CD274 ?\nLes infections virales affectent-elles CD274 ?\nLe stress chronique influence-t-il CD274 ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Patient+Acuity#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une expression anormale de CD274 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests immunohistochimiques peuvent être utilisés pour détecter CD274 dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour CD274 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dosages de cytokines et des tests de surface cellulaire peuvent évaluer CD274."
}
},
{
"@type": "Question",
"name": "CD274 est-il associé à des biomarqueurs spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 est souvent associé à des biomarqueurs de cancer comme PD-1."
}
},
{
"@type": "Question",
"name": "Quels types de cancers montrent une surexpression de CD274 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cancers du poumon, du sein et de la vessie montrent souvent une surexpression de CD274."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'impact de CD274 sur le système immunitaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études fonctionnelles sur les lymphocytes T peuvent évaluer l'impact de CD274."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une surexpression de CD274 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surexpression de CD274 peut entraîner une immunosuppression et des infections fréquentes."
}
},
{
"@type": "Question",
"name": "CD274 influence-t-il les symptômes des maladies auto-immunes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 peut exacerber les symptômes des maladies auto-immunes en inhibant les cellules T."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au cancer liés à CD274 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure la fatigue, la perte de poids et des douleurs localisées."
}
},
{
"@type": "Question",
"name": "Comment CD274 affecte-t-il la réponse aux infections ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une expression élevée de CD274 peut réduire l'efficacité de la réponse immunitaire aux infections."
}
},
{
"@type": "Question",
"name": "Les symptômes de CD274 sont-ils visibles cliniquement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, CD274 n'a pas de symptômes visibles, mais son impact est observé par des tests."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'expression de CD274 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode spécifique pour prévenir l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Comment un mode de vie sain influence-t-il CD274 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut renforcer le système immunitaire, potentiellement régulant CD274."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins ciblant CD274 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiquement ciblant CD274."
}
},
{
"@type": "Question",
"name": "La détection précoce des cancers aide-t-elle à gérer CD274 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la détection précoce peut permettre une intervention rapide sur l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles CD274 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que l'alimentation peut moduler l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent CD274 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de PD-1 et PD-L1, comme le pembrolizumab, ciblent CD274."
}
},
{
"@type": "Question",
"name": "Comment les thérapies immunologiques agissent-elles sur CD274 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles bloquent l'interaction entre CD274 et PD-1, stimulant ainsi la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "CD274 peut-il être une cible pour la thérapie génique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches explorent la thérapie génique pour moduler l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires sont associés aux traitements ciblant CD274 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions auto-immunes et des inflammations."
}
},
{
"@type": "Question",
"name": "Les traitements de CD274 sont-ils efficaces pour tous les cancers ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'efficacité varie selon le type de cancer et le profil immunitaire du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à une surexpression de CD274 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent une immunosuppression accrue et une progression tumorale."
}
},
{
"@type": "Question",
"name": "CD274 peut-il aggraver des maladies existantes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 peut aggraver des maladies auto-immunes et des infections chroniques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de résistance aux traitements avec CD274 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la surexpression de CD274 peut entraîner une résistance aux thérapies immunologiques."
}
},
{
"@type": "Question",
"name": "Comment CD274 influence-t-il la survie des patients ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une expression élevée de CD274 est souvent associée à un pronostic défavorable dans le cancer."
}
},
{
"@type": "Question",
"name": "Les complications de CD274 sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'expression de CD274 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents de cancer, des infections chroniques et l'âge."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il CD274 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter l'expression de CD274, surtout dans le cancer du poumon."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien entre l'obésité et CD274 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que l'obésité peut être associée à une expression accrue de CD274."
}
},
{
"@type": "Question",
"name": "Les infections virales affectent-elles CD274 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections virales peuvent induire l'expression de CD274 dans les cellules immunitaires."
}
},
{
"@type": "Question",
"name": "Le stress chronique influence-t-il CD274 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut moduler l'expression de CD274, affectant la réponse immunitaire."
}
}
]
}
]
}
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA.
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA. Electronic address: gdotti@med.unc.edu.
Department of Internal Medicine, Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210, USA. Electronic address: songguozheng2013@yahoo.com.
Royal Veterinary Collegegrid.20931.39, London, United Kingdom.
OIE/FAO International Reference Laboratory for Avian Influenza, Swine Influenza and Newcastle Disease, Animal and Plant Health Agency (APHA), Weybridge, Addlestone, Surrey, United Kingdom.
Nurses make complex triage decisions within emergency departments, which significantly affect patient outcomes. Understanding how nurses make these decisions and why they deviate from triage algorithm...
This qualitative systematic review aimed to understand decision-making processes emergency nurses use to make acuity decisions during triage assessment at initial patient presentation....
Medline, CINAHL and Academic Search Complete were systematically searched to 15th December 2022. Data were analysed using thematic synthesis. Established themes were reviewed with GRADE-CERQual to eva...
28 studies were included in the review. Data analysis uncovered three superordinate themes of holistic reasoning, situational awareness, and informed decision-making. The findings show nurses value ho...
This review presents new perspectives on nurses' decision-making processes about patient's acuity. Nurses holistically gather information about patients before translating that information into acuity...
Conscious state assessment is important for the triage of emergency patients. In this study, we measured the association between ambulance patients' conscious state and high versus lower acuity, with ...
Data were analysed from one year of emergency ambulance incidents in Perth, Western Australia. Patient conscious state at the time of paramedic arrival was compared to acuity (based on paramedic asses...
The proportion of high acuity patients increased with each step across the consciousness scale. Applying conscious state as a binary predictor of acuity, the largest increases occurred moving the thre...
Based on these proportions of high acuity patients, it is reasonable to consider patients with any altered conscious state a high priority. The value of conscious state assessment for predicting acuit...
The introduction of large language models (LLMs), such as Generative Pre-trained Transformer 4 (GPT-4; OpenAI), has generated significant interest in health care, yet studies evaluating their performa...
To determine whether an LLM can accurately assess clinical acuity in the emergency department (ED)....
This cross-sectional study identified all adult ED visits from January 1, 2012, to January 17, 2023, at the University of California, San Francisco, with a documented Emergency Severity Index (ESI) ac...
The potential of the LLM to classify acuity levels of patients in the ED based on the ESI across 10 000 patient pairs. Using deidentified clinical text, the LLM was queried to identify the patient wit...
Accuracy score was calculated to evaluate the performance of both LLMs across the 10 000-pair sample. A 500-pair subsample was manually classified by a physician reviewer to compare performance betwee...
From a total of 251 401 adult ED visits, a balanced sample of 10 000 patient pairs was created wherein each pair comprised patients with disparate ESI acuity scores. Across this sample, the LLM correc...
In this cross-sectional study of 10 000 pairs of ED visits, the LLM accurately identified the patient with higher acuity when given pairs of presenting histories extracted from patients' first ED docu...
Overcrowded emergency departments (EDs) are associated with higher morbidity and mortality and suboptimal quality-of-care. Most ED flow management strategies focus on early identification and redirect...
We performed a retrospective observational study in the ED of a Canadian tertiary trauma center where a redirection process for low-acuity patients was implemented. The process was based on a clinical...
Of 242,972 ED attendees over the study period, 9546 (8% of 121,116 post-intervention patients) were redirected to a nearby primary medical clinic. After the redirection process was implemented, length...
Implementing a redirection process for low-acuity ED patients based on a clinical support system was associated with improvements in two of four ED performance indicators....
Emergency departments (ED) worldwide have to cope with rising patient numbers. Low-acuity consulters who could receive a more suitable treatment in primary care (PC) increase caseloads, and lack of PC...
Qualitative semi-structured telephone interviews were conducted with 32 low-acuity ED consulters with no self-reported attachment to a GP. Participants were recruited from three EDs in the city center...
Interviewed patients reported heterogeneous factors contributing to their PC utilization behavior and underlying views and experiences. Participants most prominently voiced a rare need for medical ser...
Understanding reasons of low-acuity ED patients for GP non-utilization can play an important role in the design and implementation of patient-centered care interventions for PC integration. Increasing...
German Clinical Trials Register: DRKS00023480; date: 2020/11/27....
To evaluate the extent to which patient-users reporting symptoms of five severe/acute conditions requiring emergency care to an AI-based virtual triage (VT) engine had no intention to get such care, a...
A dataset of 3,022,882 VT interviews conducted over 16 months was evaluated to quantify and describe patient-users reporting symptoms of five potentially life-threatening conditions whose pre-triage h...
Healthcare intent data was obtained for 12,101 VT patient-user interviews. Across all five conditions a weighted mean of 38.5% of individuals whose VT indicated a condition requiring emergency care ha...
AI-based VT may offer a vehicle for early detection and care acuity alignment of severe evolving pathology by engaging patients who believe their symptoms are not serious, and for accelerating care re...
The leading diagnostic tool in modern ophthalmology, Optical Coherence Tomography (OCT), is not yet able to establish the evolution of retinal diseases. Our task is to forecast the progression of reti...
The purpose of this study was to predict visual acuity (VA) 90 days after presentation for patients with microbial keratitis (MK) from data at the initial clinical ophthalmic encounter....
Patients with MK were identified in the electronic health record between August 2012 and February 2021. Random forest (RF) models were used to predict 90-day VA < 20/40 [visual impairment (VI)]. Predi...
One thousand seven hundred ninety-one patients were identified. The presenting logMAR VA was on average 0.86 (Snellen equivalent and standard deviation = 20/144 ± 12.6 lines) in the affected or worse ...
RF modeling yielded good sensitivity and specificity to predict VI at 90 days which could guide clinicians about the risk of poor vision outcomes for patients with MK....
To determine factors influencing patient satisfaction scores in recipients of refractive surgery....
In this prospective survey-based study, patients who had refractive surgery at an outpatient refractive clinic completed a survey of selected questions from the Press Ganey survey and the National Eye...
Fifty-three patients were recruited over a 3-year period. Most were male (55%) and middle aged (mean age: 34 years). Eleven percent underwent photorefractive keratectomy surgery and the rest had laser...
This study found persistent high patient satisfaction score across a variation of characteristics, suggesting that optimal scores are mainstay after refractive surgery procedures with excellent visual...
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusi...
Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. Patients were followed pr...
Of 1002 patients in the registry, 941 had ≥ 1 FVC and/or DLco measurement after enrolment. The median (Q1, Q3) follow-up period was 35.1 (18.9, 47.2) months. Overall, mean estimated declines in FVC an...
Data from the IPF-PRO Registry suggest a constant rate of decline in lung function over a prolonged period, supporting the inexorably progressive nature of IPF. A graphical abstract summarising the da...
NCT01915511....
